Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmather Holdings Ltd PHRRF


Primary Symbol: C.PHRM

psychedelics
PharmaTher Holdings Ltd. is a Canada-based specialty pharmaceutical company. The Company develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting delivery methods to enhance patient outcomes. Its lead product is KETARX (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The... see more

Recent & Breaking News (CSE:PHRM)

PharmaTher announces positive topline results from clinical study of ketamine for Parkinson's Disease

Stockhouse Editorial March 24, 2022

PharmaTher Announces Positive Topline Results from Clinical Study of Ketamine for Parkinson's Disease

GlobeNewswire March 23, 2022

Revitalist and PharmaTher Announce Collaboration to Develop and Advance Novel and Standardized Ketamine Treatment Protocols for Mental Health Disorders and Chronic Pain Syndromes

Business Wire March 1, 2022

PharmaTher Announces Grant of U.S. Patent on Ketamine Formulation

GlobeNewswire February 16, 2022

PharmaTher Granted FDA Orphan Drug Designation for Ketamine to Treat Status Epilepticus

GlobeNewswire February 1, 2022

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

GlobeNewswire January 17, 2022

PharmaTher Announces FDA Approval of Investigational New Drug (IND) Application for Ketamine to Treat ALS

GlobeNewswire January 12, 2022

PharmaTher Announces Publication of Research Data for KETABET(TM)

GlobeNewswire January 4, 2022

PharmaTher Provides Update on Product Pipeline and Expected Milestones for 2022

GlobeNewswire December 21, 2021

PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch

GlobeNewswire December 20, 2021

PharmaTher Announces Positive Research Results for LSD Microneedle Patch

GlobeNewswire December 14, 2021

PharmaTher Granted New Japanese Patent for KETABET(TM) (Ketamine Combination Formulation), Strengthening Global Patent Portfolio

GlobeNewswire November 30, 2021

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

GlobeNewswire November 24, 2021

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

GlobeNewswire November 11, 2021

PharmaTher Enters into Research Collaboration Agreement with Revive Therapeutics for Development of Psilocybin Microneedle Patch

GlobeNewswire November 3, 2021

Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of Psilocybin Microneedle Patch

GlobeNewswire November 3, 2021

PharmaTher Provides Research Update on Microneedle Patch Delivery Technologies for Psychedelics

GlobeNewswire November 1, 2021

PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022

GlobeNewswire October 27, 2021

World Leading Drug Delivery Researcher Professor Ryan Donnelly Joins PharmaTher as Scientific and Technical Advisor

GlobeNewswire October 27, 2021

PharmaTher Engages Alcami for Clinical and Commercial Manufacturing of Novel Ketamine Products

GlobeNewswire October 19, 2021